Vor Biopharma Inc. (VOR) Stock Score, Valuation & Financial Research

Vor Biopharma Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for VOR

Vor Biopharma Inc. does not currently have a complete Wall Street Score. The stored market price is USD 18.56. These figures are a research snapshot, not a buy or sell recommendation.

What Vor Biopharma Inc. does

Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Vor Biopharma is a clinical-stage cell and genome engineering company that does not currently generate product revenue. It focuses on developing engineered hematopoietic stem cell therapies and CAR-T therapies for blood cancers, relying on capital raises and research collaborations to fund its ongoing research and development activities.

Products and services

  • The company develops VOR33, an engineered hematopoietic stem cell therapy, and VCAR33, a CAR-T therapy, both designed to treat acute myeloid leukemia and other blood cancers.

Customer types

Clinical trial sites; Healthcare providers.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on unnamed third-party contract manufacturing organizations for the production of clinical trial materials. Source

Business relationships and partnerships

  • Columbia University — License agreement for intellectual property and patent rights. Source
  • National Institutes of Health — License agreement for intellectual property and patent rights. Source
  • Editas Medicine, Inc. — License agreement for gene editing technology. Source

Business strengths to evaluate

  • Proprietary genome engineering platform Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

VOR financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 18.56
Market capitalization:
1.01B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD 627.78M
Free cash flow:
USD -143.65M
Cash:
USD 107.86M
Total debt:
USD 2.88M
EPS:
USD -325.79

What stands out

  • Free cash flow is USD -143.65M, negative for the stored period.
  • The balance sheet shows USD 107.86M of cash versus USD 2.88M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 104.98M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for VOR

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can VOR fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is VOR likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of VOR's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research VOR

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.